Molecular tumor board assisted care for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Small Cell Lung CancerMolecular tumor board assisted care - Other
Eligibility
18 - 120
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed NSCLC. MTB uses a team of specialists to develop a personalized treatment plan for each patient.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 8 weeks, 12 weeks, and 1 year

1 year
Association of ctDNA variant allele frequency
Overall survival
Year 1
Change in guideline concordant care
Week 12
Change in quality of life (QOL)
Change in satisfaction with treatment

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Usual care recipients
1 of 2
Molecular tumor board intervention
1 of 2

Active Control

Experimental Treatment

500 Total Participants · 2 Treatment Groups

Primary Treatment: Molecular tumor board assisted care · No Placebo Group · N/A

Molecular tumor board intervention
Other
Experimental Group · 1 Intervention: Molecular tumor board assisted care · Intervention Types: Other
Usual care recipientsNoIntervention Group · 1 Intervention: Usual care recipients · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks, 12 weeks, and 1 year

Who is running the clinical trial?

Jill M KolesarLead Sponsor
3 Previous Clinical Trials
33 Total Patients Enrolled
Jill Kolesar, PharmD, MSPrincipal InvestigatorUniversity of Kentucky
1 Previous Clinical Trials

Eligibility Criteria

Age 18 - 120 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to understand the nature and purpose of the study and the potential risks and benefits.